Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer

Frontiers in Immunology(2023)10.3389/fimmu.2023.1077203Source: DataRank Database

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer is a research paper published in Frontiers in Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 32 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access32 citations

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 3.75)OA: goldTopics (72)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Qiwei Wang ORCID,Tao Jiang ORCID,Weihua Wang ORCID,Jean J. Zhao ORCID,Ziying Lin ORCID

Live enrichment

PubMed:36817465 PMC:PMC9933873 OpenAlex:https://openalex.org/W4321088004

NCI NIH HHS

Grant: P50 CA168504

NCI NIH HHS

Grant: R35 CA210057

National Institutes of Health

Grant: 5R35CA210057-03

Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer

Cancer Research Institute

Breast Cancer Research Foundation

U.S. Department of Defense

National Institutes of Health

FWCI

3.75

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.3389/fimmu.2023.1077203

publisherhttps://doi.org/10.3389/fimmu.2023.1077203

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1077203/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36817465

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9933873

Fields of Study

Cancer Immunotherapy and Biomarkersinterferon and immune responsesImmune cells in cancer03 medical and health sciences0302 clinical medicineAnimalsMiceCarcinoma, Non-Small-Cell LungCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsLung NeoplasmsMutationProtein Kinase InhibitorsTumor MicroenvironmentTumor-Associated MacrophagesAcrylamidesAniline CompoundsIndolesPyrimidinesSTING Protein

MeSH Terms

Tumor-Associated MacrophagesSTING ProteinAcrylamidesAniline CompoundsAnimalsCarcinoma, Non-Small-Cell LungIndolesLung NeoplasmsMutationPyrimidinesDrug Resistance, NeoplasmCell Line, TumorProtein Kinase InhibitorsMiceTumor MicroenvironmentErbB Receptors

Keywords

OsimertinibStingLung cancerMutantMedicineCancer researchCancerLungEpidermal growth factor receptorBiologyOncologyInternal medicineGeneErlotinibTumor-associated MacrophagesSting AgonistEgfr-mutantLung NeoplasmsIndolesImmunologyMiceSTING ProteinCarcinoma, Non-Small-Cell LungCell Line, TumorTumor MicroenvironmentAnimalsProtein Kinase InhibitorsAcrylamidesAniline CompoundsRC581-607ErbB ReceptorsPyrimidinesDrug Resistance, NeoplasmMutationImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being